Open-Shell Nanosensitizers for Glutathione Responsive Cancer Sonodynamic Therapy

Adv Mater. 2022 Apr;34(15):e2110283. doi: 10.1002/adma.202110283. Epub 2022 Mar 7.

Abstract

Deleterious effects to normal tissues and short biological half-life of sonosensitizers limit the applications of sonodynamic therapy (SDT). Herein, a new sonosensitizer (Cu(II)NS) is synthesized that consists of porphyrins, chelated Cu2+ , and poly(ethylene glycol) (PEG) to overcome the challenges of SDT. As Cu2+ contains 27 electrons, Cu(II)NS has an unpaired electron (open shell), resulting in a doublet ground state and little sonosensitivity. Overexpressed glutathione in the tumor can reduce Cu2+ to generate Cu(I)NS, leading to a singlet ground state and recuperative sonosensitivity. Additionally, PEG endows Cu(II)NS with increased blood biological half-life and enhanced tumor accumulation, further increasing the effect of SDT. Through regulating the valence state of Cu, cancer SDT with enhanced therapeutic index is achieved.

Keywords: glutathione response; nanomedicine; open shell; positron emission tomography imaging; sonodynamic therapy.

MeSH terms

  • Cell Line, Tumor
  • Glutathione
  • Humans
  • Neoplasms* / drug therapy
  • Polyethylene Glycols / therapeutic use
  • Porphyrins* / pharmacology
  • Porphyrins* / therapeutic use
  • Ultrasonic Therapy* / methods

Substances

  • Porphyrins
  • Polyethylene Glycols
  • Glutathione